View in EDS

276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

Saved in:
Bibliographic Details
Title: 276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)
Authors: Tolaney, S.M.1 (AUTHOR), de Azambuja, E.2 (AUTHOR), Emens, L.A.3 (AUTHOR), Loi, S.4 (AUTHOR), Pan, W.5 (AUTHOR), Huang, J.6 (AUTHOR), Sun, S.W.6 (AUTHOR), Lai, C.6 (AUTHOR), Schmid, P.7 (AUTHOR)
Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS664-S665. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2022.07.1860